Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin insights from selective inhibitors

Circulation Research

Volumn 93, Issue 2, 2003, Pages 148-154

  Georgiadis, Dimitris ^a   Beau, Fabrice ^b   Czarny, Bertrand ^b   Cotton, Joël ^b   Yiotakis, Athanasios ^a   Dive, Vincent ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b DIF   (France)

Author keywords

Angiotensin; Angiotensin converting enzyme; Bradykinin; Phosphinic peptide inhibitors

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; RXP 407; RXP A380; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; GENE DUPLICATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BINDING SITES; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; HUMANS; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; PHOSPHINIC ACIDS; SUBSTRATE SPECIFICITY;

EID: 0042490795     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000081593.33848.FC     Document Type: Article

References (33)

1. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years: Lewis K. Dahl memorial lecture. Hypertension. 1990;16:363-370.
2. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
3. Gavras H. Corcoran lecture: angiotensin-converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
4. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
5. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
6. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest. 2002;109:1007-1009.
7. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. 1988;85:9386-9390.
8. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
9. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267:13398-133405.
10. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II): studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
11. Deddish PA, Wang LX, Jackman HL, Michel B, Wang J, Skidgel RA, Erdos EG. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties. J Pharmacol Exp Ther. 1996;279:1582-1589.
12. Michaud A, Williams TA, Chauvet MT, Corvol P. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol. 1997;51:1070-1076.
13. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
14. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
15. Perich RB, Jackson B, Johnston CI. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol. 1994;266:201-211.
16. Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, Corvol P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA. 1999;96:4330-4335.
17. Junot C, Gonzales MF, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, Dive V. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001;297:606-611.
18. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839-844.
19. Vazeux G, Cotton J, Cuniasse P, Dive V. Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochem Pharmacol. 2001;61:835-841.
20. Cotton J, Hayashi MA, Cuniasse P, Vazeux G, Ianzer D, De Camargo AC, Dive V. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry. 2002;41:6065-6071.
21. Georgiadis D, Vazeux G, Llorens-Cortes C, Yiotakis A, Dive V. Potent and selective inhibition of zinc aminopeptidase A (EC 3.4.11.7, APA) by glutamyl aminophosphinic peptides: importance of glutamyl aminophosphinic residue in the P1 position. Biochemistry. 2000;39:1152-1155.
22. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439-449.
23. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71:1501-1507.
24. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19:692-696.
25. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry. 1991;30:7118-7126.
26. van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation. 1998;98:73-81.
27. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287:567-577.
28. Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature. 1967;216:762-766.
29. Ng KK, Vane JR. Fate of angiotensin I in the circulation. Nature. 1968;218:144-150.
30. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest. 1997;99:2375-2385.
31. Kessler SP, Gomos JB, Scheidemantel TS, Rowe TM, Smith HL, Sen GC. The germinal isozyme of angiotensin-converting enzyme can substitute for the somatic isozyme in maintaining normal renal structure and functions. J Biol Chem. 2002;277:4271-4276.
32. Erdos EG, Deddish PA, Marcic BM. Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol Metab. 1999;10:223-229.
33. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.